Search
Fingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigational[A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. … Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesProducts: DROPTON®, GENBIEMOD®Boceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnBoceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. … Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: VICTRELIS ® CAPSULAS 200 MG (MOLECULA PROTEGIDA)Cabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigationalCabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. … [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexVemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigationalAfter approval, Roche in collaboration with Genentech launched a broad development program. [L1012] … Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: ZELBORAF ® TABLETAS LACADAS DE 240 MGAsparaginase Erwinia chrysanthemi
go.drugbank.com/drugs/DB08886ApprovedInvestigational[L1448] L-asparaginase was first identified in 1963,[A236344] and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase … [L149] In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic
Synonyms: Erwinia L-asparaginase, L-asparaginase (Erwinia)Carfilzomib
go.drugbank.com/drugs/DB08889ApprovedInvestigationalChemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, P-glycoprotein inhibitorsProducts: KYPROLIS®, KARFIB®Mirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. … Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: MYRBETRIC® 50 MG TABLETAS DE LIBERACION PROLONGADA, MYRBETRIC® 25 MG TABLETAS DE LIBERACION PROLONGADATofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: XELJANZ®5MG, เซลแจนซ์ (ยาเม็ด 5 มก.)Teduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalTeduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. … Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine).
Categories: Glucagon-like Peptide-2 (GLP-2) Agonists, GLP-2 AnalogSynonyms: Gly(2)-GLP-2, (Gly2)GLP-2Ponatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic IndexProducts: ICLUSIG® 15 MG TABLETAS RECUBIERTAS